When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 16 Mar 2025
Last updated: 15 Apr 2025
15 Apr 2025

Latest UK asthma guidance provides minimal change to exacerbation management

The latest guideline update from NICE/BTS/SIGN on the management of Asthma has been released. While there are some significant changes in the approach to chronic asthma diagnosis and management, little has been changed in relation to the management of exacerbations of Asthma. The document continues to regularly link to the 2024 guidance, SIGN 158.[49]​​​

Updates of note relating to asthma exacerbations:

  • Regular FeNO testing may lead to a reduction in exacerbations.

  • In people who present with an exacerbation of undiagnosed asthma, it is recommended to start MART (Maintenance And Reliever Therapy) alongside any treatment for the acute symptoms. This is a combination of Inhaled Corticosteroid with Formoterol). This may be stepped down to ‘as needed’ post discharge.[50]

See Diagnosis: recommendations

See Management: approach

Original source of update

Summary

Definition

History and exam

Key diagnostic factors

  • shortness of breath
  • cough
  • wheeze
  • risk factors
  • progressive chest tightness
  • progressive decrease in lung function
  • tachypnoea
  • tachycardia
  • silent chest
  • accessory muscle use
  • sleep disturbance

Other diagnostic factors

  • exercise limitation
  • collapse
  • altered consciousness
  • skin symptoms
  • cyanosis
  • arrhythmia
  • hypotension
  • exhaustion
  • stridor

Risk factors

  • viral infection
  • uncontrolled asthma symptoms
  • high use of short-acting beta-2 agonists
  • inadequate use of inhaled corticosteroids
  • incorrect inhaler technique
  • low forced expiratory volume in 1 second (FEV1)
  • high bronchodilator reversibility
  • current smoker (including e-cigarettes/vapes) or exposure to second-hand cigarette smoke
  • exposure to allergens (including history of seasonal allergic rhinitis)
  • air pollution
  • poor indoor air quality
  • obesity
  • chronic rhinosinusitis
  • gastro-oesophageal reflux disease
  • confirmed food allergy
  • history of asthma
  • history of hospitalisation for asthma exacerbations
  • one or more severe exacerbations in the last 12 months
  • use of oral corticosteroids
  • poor adherence to asthma treatment
  • pregnancy
  • psychological or socioeconomic problems
  • blood eosinophils
  • elevated fractional exhaled nitric oxide (FeNO)
  • respiratory bacterial infection

Diagnostic investigations

1st investigations to order

  • arterial blood gas (in hospital)
  • peak flow (in the community and in hospital)
  • pulse oximetry (in the community and in hospital)
  • chest x-ray (in hospital)

Investigations to consider

  • full blood count (in hospital)
  • urea and electrolytes (in hospital)
  • C-reactive protein (in hospital)
  • theophylline levels (in hospital)
  • ECG (in hospital)

Treatment algorithm

Contributors

Expert advisers

Jonathan Bennett, MD

Honorary Professor of Respiratory Sciences

University of Leicester

Respiratory Consultant

Glenfield Hospital

Leicester

UK

Biography

JB is deputy medical director of the Royal College of Physicians (RCP) Invited Service Reviews, and speaker at national society meetings including the British Thoracic Society, the Primary Care Respiratory Society, and the Society for Cardiothoracic Surgery.

Disclosures

JB is deputy medical director of RCP Invited Service Reviews.

Acknowledgements

BMJ Best Practice would like to gratefully acknowledge the previous expert contributors, whose work has been retained in parts of the content:

Sourav Majumdar, MD

Clinical Assistant Professor (Affiliated)

Division of Pulmonary, Allergy and Critical Care Medicine

Department of Medicine

Stanford University School of Medicine

Stanford

Lauren Eggert, MD

Fellow

Division of Pulmonary, Allergy and Critical Care Medicine

Department of Medicine

Stanford University School of Medicine

Stanford

Disclosures

SM and LE declare that they have no competing interests.

Peer reviewers

Pujan H Patel, MD

Consultant in Respiratory Medicine

Royal Brompton Hospital

London

UK

Disclosures

PP has received speaker fees for educational lecture events from GlaxoSmithKline.

Editors

Emma Quigley

Section Editor, BMJ Best Practice

Disclosures

EQ declares that she has no competing interests.

Tannaz Aliabadi-Oglesby

Lead Section Editor, BMJ Best Practice

Disclosures

TAO declares that she has no competing interests.

Julie Costello

Comorbidities Editor, BMJ Best Practice

Disclosures

JC declares that she has no competing interests.

Adam Mitchell

Drug Editor, BMJ Best Practice

Disclosures

AM declares that he has no competing interests.

Use of this content is subject to our disclaimer